# Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

> **NCT00543959** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 346 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** MK0533
- **DRUG:** Comparator: Placebo (unspecified)
- **DRUG:** Comparator: pioglitazone

## Key facts

- **NCT ID:** NCT00543959
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 346 (ACTUAL)
- **Why stopped:** This study is being discontinued based on data suggesting that none of the doses tested demonstrated both glycemic \& body fluid benefits vs. the comparitor
- **Last updated:** 2015-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543959, "Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00543959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*